Yonemura, M., Katsumata, N., Hashimoto, H., Satake, S., Kaneko, M., Kobayashi, Y., … Hojo, T. (2009). Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: A non-inferiority trial. Japanese Journal of Clinical Oncology, 3, 443–448.
To assess the noninferiority of 1 mg granisetron injection to 3 mg granisetron injection for the treatment of acute chemotherapy-induced nausea and vomiting (CINV)
Patients were randomly assigned to two treatment arms. All patients also received dexamethasone. Researchers asked the patients directly or via phone if they experienced any emetic events within 24–36 hours following the start of administration of highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). Patients recorded their symptoms, along with use of rescue antiemetics, for six days on diary cards, which were collected at each visit.
The setting was a single site in Tokyo, Japan.
Study participants were in active treatment.
This was a single-blind, randomized parallel group trial.
The rate of complete protection from nausea and vomiting was similar in both the 1-mg and 3-mg granisetron groups.
Nausea was measured as ability or inability to take meals as usual, rather than the symptom of nausea.
Granisetron dosed at 1 mg is appropriate for treatment of acute CINV in patients with cancer.